- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
The NICE-Wide Prioritisation Board met on 16 April 2026 and concluded that an evaluation would notbe appropriate for this product.
The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to the publication of guidance in the adult population and commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate with ruxolitinib being a paediatric extension of TA1054. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 6410
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 April 2026 | Topic prioritisation. Topic de-selected |
| 16 April 2024 | Note - Note added to the project documents |
| 03 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 03 January 2024 | Topic selection |
For further information on how we select topics for development, please see our page about topic prioritisation